The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
New therapies for hemophilia
Open accessAbstract
Hemophilia A (HA) and hemophilia B (HB) are the most common severe bleeding disorders. Replacement therapy, providing the missing coagulation factor, has been the mainstay of treatment both prophylactically and to treat bleeding. Despite widespread availability of safe and effective replacement therapy, patients with HA and HB continue to experience a tremendous burden of treatment, breakthrough bleeding, and progressive joint disease, as well as high rates of inhibitor development. These remaining challenges are now being addressed by incredible advances in bioengineering. Recombinant bioengineering has led to replacement therapies with easier modes of administration, decreased immunogenicity, increased efficacy, and extended half-lives. Emicizumab, a bispecific antibody that acts as a substitutive therapy for HA, has been approved for patients with and without inhibitors. Novel compounds are in development to exploit the natural balance of hemostasis by targeting the natural anticoagulants protein C, protein S, tissue factor pathway inhibitor, and antithrombin. The substitution and rebalancing therapies provide an opportunity for steady-state hemostatic control without exposure to immunogenic clotting factor proteins. As such, they may have broader applications outside those being investigated in the clinical trial programs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Therapeutic applications of hydrogels in oral drug delivery
Sharpe, L. A., Daily, A. M., Horava, S. D., & Peppas, N. A. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.902047 · Cited by 354
Men with severe hemophilia in the United States: birth cohort analysis of a large national database
Mazepa, M. A., Monahan, P. E., Baker, J. R., Riske, B. K., & Soucie, J. M. (2016) · Blood · doi:10.1182/blood-2015-10-675140 · Cited by 117
Cited by
Alexaki, A., Hettiarachchi, G. K., Athey, J. C., Katneni, U. K., Simhadri, V., Hamasaki-Katagiri, N., Nanavaty, P., Lin, B., Takeda, K., Freedberg, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51984-2 · Cited by 78
Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity
Samelson-Jones, B. J., Finn, J. D., George, L. A., Camire, R. M., & Arruda, V. R. (2019) · JCI Insight · doi:10.1172/jci.insight.128683 · Cited by 44
Metadata
- Authors
- Weyand, A. C., & Pipe, S. W.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2019-01-31
- Volume
- 133
- Issue
- 5
- Pages
- 389-398
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2903935895
- Cited by
- 172
- References
- 2
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New therapies for hemophilia. https://app.cochat.ai/papers/10.1182/blood-2018-08-872291
- The paper
- Weyand, A. C., & Pipe, S. W. (2019). New therapies for hemophilia. Blood. https://doi.org/10.1182/blood-2018-08-872291
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.